• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制G蛋白βγ信号传导可阻断前列腺癌进展并增强紫杉醇的疗效。

Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel.

作者信息

Paudyal Prakash, Xie Qing, Vaddi Prasanna Kuma, Henry Michael D, Chen Songhai

机构信息

The Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

The Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

出版信息

Oncotarget. 2017 May 30;8(22):36067-36081. doi: 10.18632/oncotarget.16428.

DOI:10.18632/oncotarget.16428
PMID:28415604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5482639/
Abstract

Aberrant activation of G protein-coupled receptors (GPCRs) is implicated in prostate cancer progression, but targeting them has been challenging because multiple GPCRs are involved in cancer progression. In this study, we tested the effect of blocking signaling via a hub through which multiple GPCRs converge - the G-protein Gβγ subunits. Inhibiting Gβγ signaling in several castration-resistant prostate cancer cell lines (i.e. PC3, DU145 and 22Rv1), impaired cell growth and migration in vitro, and halted tumor growth and metastasis in nude mice. The blockade of Gβγ signaling also diminished prostate cancer stem cell-like activities, by reducing tumorsphere formation in vitro and tumor formation in a limiting dilution assay in nude mice. Furthermore, Gβγ blockade enhanced the sensitivity of prostate cancer cells to paclitaxel treatment, both in vitro and in vivo. Together, our results identify a novel function of Gβγ in regulating prostate cancer stem-cell-like activities, and demonstrate that targeting Gβγ signaling is an effective approach in blocking prostate cancer progression and augmenting response to chemotherapy.

摘要

G蛋白偶联受体(GPCRs)的异常激活与前列腺癌进展有关,但由于多种GPCRs参与癌症进展,靶向作用于它们一直具有挑战性。在本研究中,我们测试了通过多个GPCRs汇聚的枢纽——G蛋白Gβγ亚基来阻断信号传导的效果。在几种去势抵抗性前列腺癌细胞系(即PC3、DU145和22Rv1)中抑制Gβγ信号传导,损害了体外细胞生长和迁移,并阻止了裸鼠体内肿瘤生长和转移。Gβγ信号传导的阻断还通过减少体外肿瘤球形成和裸鼠有限稀释试验中的肿瘤形成,降低了前列腺癌干细胞样活性。此外,Gβγ阻断增强了前列腺癌细胞在体外和体内对紫杉醇治疗的敏感性。总之,我们的结果确定了Gβγ在调节前列腺癌干细胞样活性中的新功能,并证明靶向Gβγ信号传导是阻断前列腺癌进展和增强化疗反应的有效方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/072e07eaa0c0/oncotarget-08-36067-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/58724a35c79c/oncotarget-08-36067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/21bc2d993768/oncotarget-08-36067-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/62476df45d74/oncotarget-08-36067-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/d2c94825ea36/oncotarget-08-36067-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/74b954c398e7/oncotarget-08-36067-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/7f478322f1e9/oncotarget-08-36067-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/3ac218c5860a/oncotarget-08-36067-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/dca83f9ac78a/oncotarget-08-36067-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/072e07eaa0c0/oncotarget-08-36067-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/58724a35c79c/oncotarget-08-36067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/21bc2d993768/oncotarget-08-36067-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/62476df45d74/oncotarget-08-36067-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/d2c94825ea36/oncotarget-08-36067-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/74b954c398e7/oncotarget-08-36067-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/7f478322f1e9/oncotarget-08-36067-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/3ac218c5860a/oncotarget-08-36067-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/dca83f9ac78a/oncotarget-08-36067-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1e/5482639/072e07eaa0c0/oncotarget-08-36067-g009.jpg

相似文献

1
Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel.抑制G蛋白βγ信号传导可阻断前列腺癌进展并增强紫杉醇的疗效。
Oncotarget. 2017 May 30;8(22):36067-36081. doi: 10.18632/oncotarget.16428.
2
A critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer.G 蛋白βγ亚基在乳腺癌发生和转移中的关键作用。
J Biol Chem. 2011 Apr 15;286(15):13244-54. doi: 10.1074/jbc.M110.206615. Epub 2011 Feb 24.
3
Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics.靶向 Gα 和 Gβγ 亚基:癌症治疗的一种潜在方法。
Trends Pharmacol Sci. 2013 May;34(5):290-8. doi: 10.1016/j.tips.2013.02.006. Epub 2013 Apr 1.
4
Targeting G protein-coupled receptor signaling at the G protein level with a selective nanobody inhibitor.靶向 G 蛋白偶联受体信号的 G 蛋白水平的选择性纳米抗体抑制剂。
Nat Commun. 2018 May 18;9(1):1996. doi: 10.1038/s41467-018-04432-0.
5
Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.异三聚体Gα/Gβγ蛋白复合物新型抑制剂BIM-46174的抗癌活性
Cancer Res. 2006 Sep 15;66(18):9227-34. doi: 10.1158/0008-5472.CAN-05-4205.
6
Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.E-钙黏蛋白的下调通过Notch信号通路增强前列腺癌的化疗耐药性。
Chin J Cancer. 2017 Mar 29;36(1):35. doi: 10.1186/s40880-017-0203-x.
7
The G-protein βγ subunits regulate platelet function.G 蛋白 βγ 亚基调节血小板功能。
Life Sci. 2020 Dec 1;262:118481. doi: 10.1016/j.lfs.2020.118481. Epub 2020 Sep 22.
8
G protein betagamma subunits as targets for small molecule therapeutic development.G蛋白βγ亚基作为小分子治疗药物开发的靶点。
Comb Chem High Throughput Screen. 2008 Jun;11(5):382-95. doi: 10.2174/138620708784534761.
9
Loss of association between activated Galpha q and Gbetagamma disrupts receptor-dependent and receptor-independent signaling.活化的Gαq与Gβγ之间的关联丧失会破坏受体依赖性和受体非依赖性信号传导。
Cell Signal. 2005 Oct;17(10):1218-28. doi: 10.1016/j.cellsig.2004.12.008. Epub 2005 Jan 22.
10
Gβγ Pathways in Cell Polarity and Migration Linked to Oncogenic GPCR Signaling: Potential Relevance in Tumor Microenvironment.与致癌性GPCR信号传导相关的细胞极性和迁移中的Gβγ信号通路:在肿瘤微环境中的潜在相关性
Mol Pharmacol. 2016 Nov;90(5):573-586. doi: 10.1124/mol.116.105338. Epub 2016 Sep 16.

引用本文的文献

1
Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.揭示RACK1:前列腺癌发展中PI3K/AKT信号通路的关键调节因子。
Oncogene. 2025 Feb;44(5):322-335. doi: 10.1038/s41388-024-03224-9. Epub 2024 Nov 13.
2
Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets.非经典的高尔基区室化 Gβγ 信号转导:机制、功能和治疗靶点。
Trends Pharmacol Sci. 2023 Feb;44(2):98-111. doi: 10.1016/j.tips.2022.11.003. Epub 2022 Dec 7.
3
The olfactory receptor OR51E2 activates ERK1/2 through the Golgi-localized Gβγ-PI3Kγ-ARF1 pathway in prostate cancer cells.

本文引用的文献

1
Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.提高去势抵抗性前列腺癌的紫杉烷类化疗效果。
Trends Pharmacol Sci. 2016 Jun;37(6):451-462. doi: 10.1016/j.tips.2016.03.003. Epub 2016 Apr 8.
2
Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.上调的WDR26作为一种支架,协调PI3K/AKT信号通路驱动的乳腺癌细胞生长、迁移和侵袭。
Oncotarget. 2016 Apr 5;7(14):17854-69. doi: 10.18632/oncotarget.7439.
3
Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
嗅觉受体OR51E2通过高尔基体定位的Gβγ-PI3Kγ-ARF1途径激活前列腺癌细胞中的ERK1/2。
Front Pharmacol. 2022 Oct 13;13:1009380. doi: 10.3389/fphar.2022.1009380. eCollection 2022.
4
G protein βγ translocation to the Golgi apparatus activates MAPK via p110γ-p101 heterodimers.G 蛋白 βγ 亚基向高尔基体的易位通过 p110γ-p101 异源二聚体激活 MAPK。
J Biol Chem. 2021 Jan-Jun;296:100325. doi: 10.1016/j.jbc.2021.100325. Epub 2021 Jan 23.
5
Elimination of SOX2/OCT4-Associated Prostate Cancer Stem Cells Blocks Tumor Development and Enhances Therapeutic Response.消除与SOX2/OCT4相关的前列腺癌干细胞可阻断肿瘤发展并增强治疗反应。
Cancers (Basel). 2019 Sep 8;11(9):1331. doi: 10.3390/cancers11091331.
6
Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways.MUC15通过GPCR/ERK和整合素-FAK信号通路促进甲状腺癌的肿瘤进展和癌症干性。
Oncogenesis. 2018 Nov 12;7(11):85. doi: 10.1038/s41389-018-0094-y.
7
Targeting G protein-coupled receptor signalling by blocking G proteins.靶向 G 蛋白偶联受体信号转导的 G 蛋白阻断剂。
Nat Rev Drug Discov. 2018 Nov;17(11):789-803. doi: 10.1038/nrd.2018.135. Epub 2018 Sep 28.
前列腺癌干细胞样细胞促成去势抵抗性前列腺癌的发展。
Cancers (Basel). 2015 Nov 18;7(4):2290-308. doi: 10.3390/cancers7040890.
4
Prostate Cancer Stem Cells: Research Advances.前列腺癌干细胞:研究进展
Int J Mol Sci. 2015 Nov 17;16(11):27433-49. doi: 10.3390/ijms161126036.
5
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.前列腺癌中对雄激素受体抑制剂耐药的新机制
Nat Rev Cancer. 2015 Dec;15(12):701-11. doi: 10.1038/nrc4016. Epub 2015 Nov 13.
6
Concurrent chemoradiation for high-risk prostate cancer.高危前列腺癌的同步放化疗
World J Clin Oncol. 2015 Aug 10;6(4):35-42. doi: 10.5306/wjco.v6.i4.35.
7
Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.前列腺特异性G蛋白偶联受体与PTEN缺失协同作用促进前列腺癌进展。
Oncogene. 2016 Mar 3;35(9):1153-62. doi: 10.1038/onc.2015.170. Epub 2015 Jun 1.
8
The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.PI3K/Akt和MAP激酶信号通路的上调与前列腺癌中微管靶向药物的耐药性相关。
J Cell Biochem. 2015 Jul;116(7):1341-9. doi: 10.1002/jcb.25091.
9
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.前列腺癌干细胞:解读前列腺肿瘤发生和侵袭的起源及相关途径。
Oncotarget. 2015 Feb 10;6(4):1900-19. doi: 10.18632/oncotarget.2953.
10
Prostate cancer: The androgen receptor remains front and centre.前列腺癌:雄激素受体仍然是核心要点。
Nat Rev Clin Oncol. 2013 Mar;10(3):126-8. doi: 10.1038/nrclinonc.2013.14. Epub 2013 Feb 5.